Medico Remedies (MEDICO) Share Price falls 10.18% as stock drops to Rs 23.48

Published:   28 September 2026 at 9:54:34 AM IST

Medico Remedies Share Price declined to Rs 23.48 on 28 September 2026, down 10.18% from the previous close, as the company’s market capitalisation stood at Rs 216.92 crore. The move makes Medico Remedies Stock News relevant for readers tracking a Micro Cap name in the Healthcare sector and the Pharmaceuticals & Drugs industry. The latest Medico Remedies Share Price Today action confirms a clear one-day fall, while the supplied data does not establish a company-specific catalyst. Univest is tracking the move with the verified market data, including the day’s open, high, low and turnover, so investors can read the event in context rather than through assumptions. In this Medico Remedies Share Price note, the focus is on what the numbers show, what they do not show, and how the stock compares with sector and peer benchmarks.

Medico Remedies (MEDICO) Share Price Today: Price Action Analysis

Metric	Value
Current Price	Rs 23.48
Previous Close	Rs 26.14
Today's Move	-Rs 2.66 (-10.18%)
Open	Rs 26.24
High	Rs 26.24
Low	Rs 22.65
Turnover	Rs 0.09 crore
Market Capitalisation	Rs 216.92 crore
Market Cap Category	Micro Cap

Medico Remedies Share Price Today opened at Rs 26.24, exactly at the day’s high, and then moved lower through the session to close at Rs 23.48. The stock finished Rs 2.66 below the previous close of Rs 26.14, a decline of 10.18%. The day’s low was Rs 22.65, which places the closing price closer to the lower end of the intraday range than to the opening level. That pattern confirms a weak close relative to the starting point for the session.

The day’s turnover was Rs 0.09 crore, and the company remains in the Micro Cap category. On a pure price basis, the Medico Remedies Share Price moved from Rs 26.24 at the open to a low of Rs 22.65 before settling at Rs 23.48. The event is significant because it marks a sharp same-day share price decline in a small company with a market cap of Rs 216.92 crore. The supplied data confirms the move but does not establish a company-specific reason. For readers following Medico Remedies Stock Price action, the next step is to check whether the decline is isolated to one session or part of a broader trend in subsequent market updates through Univest.

Medico Remedies (MEDICO) Fundamental Analysis

Metric	Value
Market Capitalisation	Rs 216.92 crore
P/E Ratio	15.7x
P/B Ratio	2.78x
ROE	19.02%
ROCE	23.28%
EPS	Rs 1.66
Book Value Per Share	Rs 9.4
Dividend Yield	0%

Medico Remedies Share Price today needs to be read alongside its valuation and profitability metrics. The stock trades at a P/E ratio of 15.7 and a P/B ratio of 2.78, while the market capitalisation is Rs 216.92 crore. EPS stands at Rs 1.66 and book value per share is Rs 9.4, which gives a direct accounting and earnings context to the current Medico Remedies Share Price. Dividend yield is 0, so the present data does not show a cash yield contribution in the valuation framework.

Return ratios are also important in the Medico Remedies Fundamental Analysis. ROE is 19.02% and ROCE is 23.28%, both of which sit above the company’s book-value base and show the operating return context in the supplied figures. The latest fundamentals do not explain the day’s fall on their own, but they do show why the stock can remain on the watchlist even after a sharp decline. In Univest’s framing, the point of Medico Remedies Share Price analysis is to separate price movement from financial facts. Revenue, profit growth and other operating detail are not supplied here, so the present note stays anchored to the verified metrics that are available.

Sector and Industry Context

Metric	Value
Sector	Healthcare
Industry	Pharmaceuticals & Drugs
Benchmark Scope	same industry
Company P/E Ratio	15.7x
Benchmark Median P/E	32.87x
Benchmark Average P/E	49.63x
Benchmark P/E Range	3.46x to 735.85x
Company P/B Ratio	2.78x
Benchmark Median P/B	2.85x
Benchmark Average P/B	4.33x
Company ROE	19.02%
Benchmark Median ROE	11.48%
Benchmark Average ROE	10.04%
Company ROCE	23.28%
Benchmark Median ROCE	13.17%
Benchmark Average ROCE	12.82%
Company Market Capitalisation	Rs 216.92 crore
Benchmark Median Market Cap	Rs 732.57 crore
Benchmark Average Market Cap	Rs 14,043.26 crore

Medico Remedies operates in Healthcare and the Pharmaceuticals & Drugs industry, where the supplied benchmark scope covers 204 companies in the same industry. In that benchmark set, the company’s P/E of 15.7 sits below the median of 32.87 and below the average of 49.63, while remaining within the observed range of 3.46 to 735.85. Its P/B of 2.78 is slightly below the benchmark median of 2.85 and below the average of 4.33. These comparisons give useful context to the Medico Remedies Share Price fall without turning the move into a forecast.

The return ratios compare favourably within the supplied benchmark. Medico Remedies reports ROE of 19.02% against the sector median of 11.48% and sector average of 10.04%, while ROCE of 23.28% is above the sector median of 13.17% and average of 12.82%. The company’s market cap of Rs 216.92 crore is also well below the benchmark median market cap of Rs 732.57 crore and far below the benchmark average of Rs 14,043.26 crore. Univest reads these facts as a valuation-and-quality snapshot, not as a prediction. For Medico Remedies Share Price watchers, the sector context shows that the same-day fall occurred against a backdrop of relatively modest valuation multiples and stronger return ratios than the benchmark median.

Peer Comparison

Company	Symbol	Market Cap (Cr)	P/E	P/B	ROE (%)	ROCE (%)
Sun Pharmaceutical Industries	SUNPHARMA	4,44,716.74	36.77	5.14	14.85	19.11
Divi's Laboratories	DIVISLAB	2,55,115.31	87.22	14.44	16.19	21.51
Torrent Pharmaceuticals	TORNTPHARM	1,89,613.38	86.94	21.13	26.76	19.27
Zydus Lifesciences	ZYDUSLIFE	1,19,899.96	26.57	4.45	19.69	21.39
Cipla	CIPLA	1,12,875.68	33.49	3.21	11.83	16

Among the supplied peers, Medico Remedies has the smallest market capitalisation at Rs 216.92 crore, below Zydus Lifesciences at Rs 1,19,899.96 crore, Cipla at Rs 1,12,875.68 crore, Lupin at Rs 95,573.6 crore, Sun Pharmaceutical Industries at Rs 4,44,716.74 crore, Divi’s Laboratories at Rs 2,55,115.31 crore, Torrent Pharmaceuticals at Rs 1,89,613.38 crore, Aurobindo Pharma at Rs 98,464.42 crore, and Mankind Pharma at Rs 1,02,247.25 crore. On this measure alone, the company sits far below the peer group scale.

Its P/E of 15.7 is lower than every listed peer in the supplied set, including Lupin at 17.29, Zydus Lifesciences at 26.57, Sun Pharmaceutical Industries at 36.77 and Cipla at 33.49. The company’s ROE of 19.02% and ROCE of 23.28% are also above several peers, though below Lupin on both measures and below Torrent Pharmaceuticals on ROE. In Univest’s peer view, Medico Remedies Share Price stands out more for its lower valuation than for company scale. That is the main comparison point available from the verified data.

Why Investors Are Watching Medico Remedies

• Medico Remedies Share Price fell 10.18% to Rs 23.48 on 28 September 2026.
• The stock moved from an open of Rs 26.24 to a low of Rs 22.65 during the session.
• Market capitalisation stood at Rs 216.92 crore, placing it in the Micro Cap category.
• P/E is 15.7 and P/B is 2.78, which frame the current Medico Remedies Share Price.
• ROE is 19.02% and ROCE is 23.28%, both above the sector benchmark median.

About Medico Remedies

Medico Remedies is classified in Healthcare and the Pharmaceuticals & Drugs industry. The current update identifies it as a Micro Cap company with a market capitalisation of Rs 216.92 crore. The stock trades on NSE and BSE as MEDICO, and the article focuses on the verified market move, valuation ratios and sector context supplied in the data. For readers following Medico Remedies Share Price or Medico Remedies Stock News, the key point is that the event is a same-day price fall, not a broader corporate update.

Univest keeps the company in view through share price tracking, fundamental ratios and peer context, allowing readers to follow Medico Remedies Share Price movements alongside sector benchmarks and market capitalisation.

Track Medico Remedies Share Price on Univest

Use Medico Remedies (MEDICO) live share-price page,Univest top decliners screener,Univest market blogs to review live stock data, top decliners and related market analysis.

You can track Medico Remedies Share Price on Univest for live price updates, company fundamentals, shareholding pattern, 52-week levels and market insights. Univest brings the latest Medico Remedies Share Price Today view together with valuation ratios, peer comparison and stock analysis in one place for easy reference.

Frequently Asked Questions

Why did Medico Remedies Share Price fall today?

Ans.  The data confirms that Medico Remedies Share Price fell 10.18% to Rs 23.48, but it does not establish a company-specific catalyst. The article therefore treats the move as a verified same-day decline.

What is Medico Remedies Share Price today?

Ans.  Medico Remedies Share Price today is Rs 23.48. It closed below the previous close of Rs 26.14 after opening at Rs 26.24 and touching an intraday low of Rs 22.65.

What does Medico Remedies market cap show?

Ans.  Medico Remedies has a market capitalisation of Rs 216.92 crore, which places it in the Micro Cap category. Market cap indicates company size, not quality, so it should be read alongside valuation and return ratios.

How do Medico Remedies valuation ratios look?

Ans.  Medico Remedies trades at a P/E of 15.7 and a P/B of 2.78. In the supplied industry benchmark, both sit below the median levels, which gives the current Medico Remedies Share Price a valuation context.

What do ROE and ROCE say about Medico Remedies?

Ans.  Medico Remedies reports ROE of 19.02% and ROCE of 23.28%. Both are above the benchmark median for the same industry, so the company’s return metrics compare favourably within the supplied dataset.

Does Medico Remedies pay a dividend?

Ans.  The dividend yield is 0, so the supplied data does not show a dividend yield contribution. Investors tracking Medico Remedies Share Price should therefore focus on earnings, book value and valuation multiples in the current update.